Short-term celecoxib (celebrex) adjuvant therapy: a clinical trial study on COVID-19 patients-Reference-Cited by-同舟云学术

Short-term celecoxib (celebrex) adjuvant therapy: a clinical trial study on COVID-19 patients

Published:2022-07-14 Issue:5 Volume:30 Page:1645-1657
ISSN:0925-4692
Container-title:Inflammopharmacology
language:en
Short-container-title:Inflammopharmacol

Author:

Ghaznavi Habib,Mohammadghasemipour Zahra,Shirvaliloo Milad,Momeni Mohammad Kazem,Metanat Malihe,Gorgani Farzaneh,Abedipour Fatemeh,Mohammadi Mahdi,Sartipi Majid,Khorashad Ali Reza Salimi,Shahraki Omolbanin,Ataee Mohadese,Sheervalilou Roghayeh^ORCID,Sargazi Saman

Funder

Zahedan University of Medical Sciences

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Immunology

Link

https://link.springer.com/content/pdf/10.1007/s10787-022-01029-4.pdf

Reference46 articles.

1. Abualhasan M, Zatar N, Shehab KA, Shraim N (2021) Tablet formulation of a synthesized celecoxib potassium salt and development of a validated method for its analysis. Curr Pharm Des 27(25):2872–2880

2. Al Saleh K, AlQahtani RM (2021) Platelet count patterns and patient outcomes in sepsis at a tertiary care center: beyond the APACHE score. Medicine 100(18):e25013

3. Al-Hakeim HK, Al-Hamami SA, Almulla AF, Maes M (2021) Increased serum thromboxane A2 and prostacyclin but lower complement C3 and C4 levels in COVID-19: associations with chest CT scan anomalies and lowered peripheral oxygen saturation. COVID 1(2):489–502